Although the use of RAS inhibitors such as ACEIs/ARBs has been shown to increase the expression of ACE2 in some animal studies 90, 91, the use of RAS inhibitors has been recommended in CVD patients with COVID-19 since there has been no clinical evidence that the use of RAS inhibitors increases the susceptibility to SARS-CoV-2 infection 92, 93. This evidence concerns the gene ACE2 and COVID-19.